Last updated on August 2018

Study of E7386 in Subjects With Selected Advanced Neoplasms

Brief description of study

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.

Clinical Study Identifier: NCT03264664

Contact Investigators or Research Sites near you

Start Over

Eisai Medical Information

The Christie NHS Foundation Trust
Manchester, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.